Pipeline & Product
Pipeline & Product
Development Candidate (Indication)
Pre-Clinical
Phase 1
Phase 2
Phase 3
NDA Review
Status
LPCN 1154
Postpartum depression
Phase 3
Topline results Q2/26
LPCN 2101
Women With Epilepsy
IND cleared for P2
LPCN 2401
Obesity Management – adjunct to GLP-1
POC study with GLP-1 — expected patient dosing
LPCN 1148
Decompensated Liver Cirrhosis
P2 study completed
LPCN 1107
Prevention of preterm birth
EOP2 meeting completed
LPCN 2203
Essential Tremor
P1 study completed
Product
Pre-Clinical
Phase 1
Phase 2/POC
Pivotal
Approved
Status
TLANDO
TRT
Marketed
Focus on enhancing health
We are pioneers of developing innovative drug products targeting significant unmet medical needs.